Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials

Qinglin Cheng; Junfang Chen; Qingjun Jia; Zijian Fang; Gang Zhao

doi:doi:10.18632/aging.203522

← Back

COVID-19 Research Paper Volume 13, Issue 18 pp 21866—21902

Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials

Figure 5. Network meta-analyses of the relative efficacy and safety of medications in severe COVID-19 patients. (A) All-cause mortality. (B) The ratio of treatment-emergent adverse events. Abbreviations: COVID-19: coronavirus disease 2019; OR: odds ratio; CI: confidence interval; LS: low dosage sarilumab; HS: high dosage sarilumab; CP: convalescent plasma; ALA: α-Lipoic acid; IG: immunoglobulin gamma.